摘要
目的观察阿德福韦酯联合拉米夫定治疗慢性乙型肝炎的安全性及临床疗效。方法 68例CHB患者被分为A组34例,口服阿德福韦酯治疗;B组34例口服阿德福韦酯联合拉米夫定治疗,观察48周。结果治疗12周、24周和48周时,A组和B组患者HBV DNA阴转率分别为5.9%、26.5%、32.4%和61.8%、47.1%、82.4%;HBeAg阴转率分别为5.9%、8.8%、17.6%和20.6%、26.5%、32.4%;血清ALT复常率分别为11.8%3、5.3%、41.2%和73.5%、55.9%、88.2%。结论阿德福韦酯联合拉米夫定治疗慢性乙型肝炎比单用阿德福韦酯具有更好的短期临床疗效。
0bjective To evaluate the therapeutic effect and safety of adefovir dipivoxil（ADV）plus lamivudine（LAM）for the treatment of patients with chronic hepatitis B.Methods 34 patients in group A received ADV,while 34 patients in group B received ADV and LAM for 48 weeks.Results At week 12,24 and 48,HBV DNA negative rates in group A and B were 5.9%,26.5%,32.4% and 61.8%,47.1%,82.4%,respectively;HBeAg negative rate were 5.9%,8.8%,17.6% and 20.6%,26.5%,32.4%;ALT normalization rate were 11.8%,35.3%,41.2% and 73.5%,55.9%,88.2%,respectively.Conclusion ADV plus LAM is a safe and effective therapy in patients with CHB.
出处
《实用肝脏病杂志》
CAS
2011年第3期185-186,共2页
Journal of Practical Hepatology
